This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

A Surgical Infection Society Policy Statement

John M. A. Bohnen, MD; Joseph S. Solomkin, MD; E. Patchen Dellinger, MD; H. Stephen Bjornson, MD, PhD; Carey P. Page, MD

Arch Surg. 1992;127(1):83-89.

Abstract
• Several antibiotics have been marketed for therapeutic use in intra-abdominal infection. Often, these agents do not provide a sufficient spectrum activity against both facultative and obligate anaerobic gram-negative organisms, or have certain toxic effects that would not otherwise support their use. Guidelines have been developed for selection of antibiotic therapy for intra-abdominal infections and are presented as a statement of the Surgical Infection Society endorsed by the Executive Council. These guidelines are restricted to infections derived from the gastrointestinal tract and deal with those microorganisms commonly seen in such infections. The recommendations are based on in vitro activity against enteric bacteria, experience in animal models, and documented efficacy in clinical trials. Other concerns regarding pharmacokinetics, mechanisms of action, microbial resistance, and safety were also used in the formation of these guidelines. For community-acquired infections of mild to moderate severity, single-agent therapy with cefoxitin, cefotetan, or cefmetazole or ticarcillin—clavulanic acid is recommended. For more severe infections, single-agent therapy with carbapenems (imipenem/cilastatin) or combination therapy with either a third-generation cephalosporin, a monobactam (aztreonam), or an aminoglycoside plus clindamycin or metronidazole is recommended. Regimens with little or no activity against facultative gram-negative rods or anaerobic gram-negative rods are not considered acceptable.

(Arch Surg. 1992;127:83-89)

Author Affiliations
From the University of Toronto (Ontario) Faculty of Medicine, Department of Surgery (Dr Bohnen); Department of Surgery, University of Cincinnati (Ohio) College of Medicine (Drs Solomkin and Bjornson); Department of Surgery, University of Washington School of Medicine, Seattle (Dr Dellinger); and Department of Surgery, University of Texas Health Sciences Center, San Antonio (Dr Page).

Footnotes
Accepted for publication August 4, 1991.

This article was prepared by the Antimicrobial Agents Committee of the Surgical Infection Society.

Reprint requests to Department of Surgery, University of Cincinnati Medical Center, 231 Bethesda Ave (ML 558), Cincinnati, OH 45267-0558 (Dr Solomkin).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Aminoglycoside-Based Triple-Antibiotic Therapy Versus Monotherapy for Children With Ruptured Appendicitis
Goldin et al.
Pediatrics 2007;119:905-911.
ABSTRACT | FULL TEXT  

Microdialysis Study of Imipenem Distribution in the Intraperitoneal Fluid of Rats with or without Experimental Peritonitis
Lefeuvre et al.
Antimicrob. Agents Chemother. 2006;50:34-37.
ABSTRACT | FULL TEXT  

Severe Trauma Is Not an Excuse for Prolonged Antibiotic Prophylaxis
Velmahos et al.
Arch Surg 2002;137:537-542.
ABSTRACT | FULL TEXT  

Pharmacokinetics of ceftazidime in serum and peritoneal exudate during continuous versus intermittent administration to patients with severe intra-abdominal infections
Buijk et al.
J Antimicrob Chemother 2002;49:121-128.
ABSTRACT | FULL TEXT  

It's Time to Sweat the Little Things
Weigelt
Arch Surg 2000;135:763-764.
FULL TEXT  

Bioavailability of Oral Ciprofloxacin in Early Postsurgical Patients
Hackam et al.
Arch Surg 1998;133:1221-1225.
ABSTRACT | FULL TEXT  

Prospective Alterations in Therapy for Penetrating Abdominal Trauma
Nichols et al.
Arch Surg 1993;128:55-64.
ABSTRACT